CAS: 26116-56-3; Erythromycylamine
该化合物是红血球的衍生物,是一种大型抗生素,该化合物具有抗菌性,主要针对一系列抗乳细胞和某些抗乳性生物,主要针对抗菌性细菌和某些抗乳性生物.抑制细菌蛋白合成,从而阻止细菌生长和复制,防止细菌生长和复制;其结构特征是红血球,其特征是红血球素,经过改造,包括一个能够加强其药理特征的矿物质组.该化合物通常在临床环境中用于治疗各种感染,特别是呼吸道感染,皮肤感染和某些性传播疾病.
- 英文名称Erythromycylamine
- 中文名称(9S)-红霉胺
- IUPAC名称(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-10-amino-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
- 其它别名(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-10-Amino-6-{[(2S,3R,4S,6R)-4-(Dimethylamino)-3-Hydroxy-6-Methyltetrahydro-2H-Py Ran-2-Yl]Oxy}-14-Ethyl-7,12,13-Trihydroxy-4-{[(2R,4R,5S,6S)-5-Hydroxy-4-Methoxy-4,6-Dimethyltetrahydro-2H-Pyran-2-Yl]Oxy }-3,5
- CAS编号26116-56-3
- MFCD编号:MFCD00872156
- EINECS号:406-790-7
- FDA UNII编号:YX9KV1OMA4
- 分子式:C37H70N2O12分子量:734.96
- 产品CID: 1229628
- 产品分类有机原料→分子砌块→脂肪杂环类化合物→四氢吡喃类化合物
相似化合物
128940-83-0 26116-56-3 200802-92-2物理性质
- 熔点123-127 °C
- 沸点810.3±65.0 °C at 760 mmHg
- 闪点443.8 °C
- 密度1.19g/cm3
- pKa:13.41±0.70(预测)
- PSA:202.86
- LogP:1.5438
- 折射率1.539
- 蒸汽压2.15E-30mmHg at 25°C
- 溶解性DMF: 15 mg/mL; DMSO: 15 mg/mL; Ethanol: 30 mg/mL; Ethanol:Pbs (Ph 7.2) (1:1): 0.5 mg/mL
- 外观形态白色至类白色固体
- 储存条件请置于阴暗处, 惰性气氛中,冷冻保存, 低于 -20°C
- 产品应用该化合物是一种大型硫化抗生素,是一种活性二硝基苯丙胺代谢物,对各种细菌,包括S. 阴原菌株,S.肺炎,L. 单细胞原体和B. 百日咳积极防治,还积极防治与艾滋病病人隔离的M. AVIUM综合体(MAC)的28个临床分离物,乙烯酰胺抑制了在无细胞试验中多晶素和聚丙胺合成.
MSDS等安全信息
- GHS象形图
- GHS符号GHS05 & GHS09;
注释: Corrosion & Environment - 危险类别严重眼损伤 类别1
水生急性毒性 类别1
水生慢性毒性 类别1 - 警示词Danger(危险)
- 危险描述H318 |造成严重眼损伤.
H400 |对水生生物毒性极大.
H410 |对水生生物毒性极大并具有长期持续影响. - 防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
- UN编号3077
- 危险品标志Xi,N
- 安全声明26-39-60-61
- 危险类别码41-50/53
欧盟法规
统一分类与标签REACH注册ECHA物质工作场所安全标识要求ECHA物质C&L通报REACH预注册废弃物危险特性清单上下游产品
CAS号78443-21-7 | CAS号801972-88-3 α-[2]naphthylam... | CAS号111869-04-6 4-acetyl-L-cladinose | CAS号78443-20-6 (2S,3R,4S,6R)-4... | CAS号78479-30-8 N-((2R,3S,4R,5S... | CAS号78443-16-0 N-((1S,2R,5R,6S... | CAS号78443-18-2 N-((2R,3S,4R,5S... | CAS号114-07-8 红霉素合成工艺路线路线简述
📜红霉素置于吡啶,Titanium(III) Chloride,盐酸羟胺,Sodium Cyanoborohydride体系中,化学反应 30.0H,反应生成(9S)-9-氨基-9-脱氧乙琥红霉素
参考文献:大环内酯与核碱基或核苷的杂种
标题:大环内酯与核碱基或核苷的杂种
摘要:报道了红霉素a衍生物和核碱基(尿嘧啶和胸腺嘧啶)或胸苷衍生的核苷的杂合体/结合物/嵌合体的一些实例.研发了接头和反应条件,以避免大环内酯部分的降解(糖苷水解,环裂解,脱水等).
Doi:10.1016/s0040-4039(00)00417-2
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2004075874-A1
优先权日:2003-02-28
标题 :Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
发明人：MENEKSE OKTAY
权利人:ANBICS PATENTS LICENCES AG; MENEKSE OKTAY
摘要:Macrolides, in particular azalides such as azithromycin, are suited for the treatment or prevention of acute or chronic P. aeruginosa infections of the airways by inhalaÂtion. The mechanism of action is the inhibition of the quoÂrum sensing of P. aeruginosa, in particular the impediment of the las and rhl quorum sensing systems synthesis and the impediment of the synthesis of the autoinducers N-[3-oxodoÂ1o decanoyl]-L-homoserine lactone and N-butyrylhomoserine lacÂtone. This allows for inhalation treatments of P. aerugi-nosa infections at non-inhibiting concentrations of the macrolide.
专利号:RU-2131878-C1
优先权日:1993-12-08
标题:9a-n-(n'-carbamoyl)- or 9a-n-(n'-thiocarbanoyl)-derivatives of 9-deoxo-9a-aza-9a-homoerythromycin a, method of their synthesis and pharmaceutical composition based on said
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1. Hardy, D.J., Hensey, D.M., Beyer, J.M., et al. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32(11), 1710-1719 (1988). 2. Naik, S., and Ruck, R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob. Agents Chemother. 33(9), 1614-1616 (1989). 3. Matijašević, P., Franjić, N., Đokić, S., et al. Erythromycin series. X. Inhibitory activity of several new erythromycin derivatives in cell-free amino acid polymerization systems. Croat. Chem. Acta 53(3), 519-524 (1980).合成参考文献
摘要:European Journal of Medicinal Chemistry--Chimie Therapeutique., 13(83), 1978
📝 需求与反馈
尽可能描述清楚需求与问题信息
